Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FILANA THERAPEUTICS, INC.SAVA · Entity 7294 | Director · Chief Medical Officer | December 31, 2022 | January 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FILANA THERAPEUTICS, INC.
Report date December 31, 2022 · Filed January 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,910 |
Ending reported balance
After 2022-03-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-01-31 · Gift · Disposed 10 · Balance 79,900 F1: Bona Fide Gift Row 2 · 2022-03-15 · Gift · Disposed 990 · Balance 78,910 F1: Bona Fide Gift |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 143 |
Reported balance
Holding disclosure · report date 2022-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 143 |
Filing footnotes · ownership attribution and instrument terms
F1: Bona Fide Gift
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2022 Filed Oct 3, 2022 22:01 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock · Derivative | 9,376 | $0.95 Strike: $0.95 | $8,907.20 |
DisclosureSEC source: 0001069530-22-000049 · certent-form4.xml · derivative · entry 3 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,624 Underlying: Common Stock · 9,376 shares Expires 2028-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 22:01 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock | 9,376 | $0.95 | $8,907.20 |
DisclosureSEC source: 0001069530-22-000049 · certent-form4.xml · nonDerivative · entry 1 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction represents exercise of stock options for cash. Read SEC document |
| May 27, 2022 Filed May 31, 2022 20:20 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock · Derivative | 24,513 | $23.38 Strike: $23.38 | $573,113.94 |
DisclosureSEC source: 0001069530-22-000027 · certent-form4.xml · derivative · entry 7 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,513 shares Expires 2022-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2022 Filed May 31, 2022 20:20 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock · Derivative | 3,501 | $23.38 Strike: $23.38 | $81,853.38 |
DisclosureSEC source: 0001069530-22-000027 · certent-form4.xml · derivative · entry 6 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,501 shares Expires 2022-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2022 Filed May 31, 2022 20:20 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Tax withholdingCommon Stock | 21,498 | $26.66 | $573,136.68 |
DisclosureSEC source: 0001069530-22-000027 · certent-form4.xml · nonDerivative · entry 4 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,534 F1 · balance_after: Form 4 represents net exercise of stock options only. No shares of common stock were sold to third parties in this transaction. Read SEC document |
| May 27, 2022 Filed May 31, 2022 20:20 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Tax withholdingCommon Stock | 3,071 | $26.66 | $81,872.86 |
DisclosureSEC source: 0001069530-22-000027 · certent-form4.xml · nonDerivative · entry 3 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,032 F1 · balance_after: Form 4 represents net exercise of stock options only. No shares of common stock were sold to third parties in this transaction. Read SEC document |
| May 27, 2022 Filed May 31, 2022 20:20 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock | 24,513 | $23.38 | $573,113.94 |
DisclosureSEC source: 0001069530-22-000027 · certent-form4.xml · nonDerivative · entry 2 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2022 Filed May 31, 2022 20:20 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock | 3,501 | $23.38 | $81,853.38 |
DisclosureSEC source: 0001069530-22-000027 · certent-form4.xml · nonDerivative · entry 1 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2022 Filed Jan 3, 2023 21:16 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GiftCommon Stock | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0001069530-23-000002 · certent-form5.xml · nonDerivative · entry 2 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,910 F1 · price: Bona Fide Gift Read SEC document |
| January 31, 2022 Filed Jan 3, 2023 21:16 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GiftCommon Stock | 10 | $0.00 | $0.00 |
DisclosureSEC source: 0001069530-23-000002 · certent-form5.xml · nonDerivative · entry 1 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,900 F1 · price: Bona Fide Gift Read SEC document |
| March 24, 2021 Filed Feb 3, 2022 22:11 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GiftCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001069530-22-000007 · certent-form5.xml · nonDerivative · entry 1 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,089 F1 · price: Bona Fide Gift Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 20:06 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock · Derivative | 28,015 | $53.55 Strike: $53.55 | $1,500,203.25 |
DisclosureSEC source: 0001069530-21-000016 · certent-form4.xml · derivative · entry 3 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,015 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 20:06 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Tax withholdingCommon Stock | 23,996 | $62.52 | $1,500,229.92 |
DisclosureSEC source: 0001069530-21-000016 · certent-form4.xml · nonDerivative · entry 2 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,429 F1 · balance_after: Form 4 represents net exercise of stock options only. No shares of common stock were sold to third parties in this transaction. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 20:06 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock | 28,015 | $53.55 | $1,500,203.25 |
DisclosureSEC source: 0001069530-21-000016 · certent-form4.xml · nonDerivative · entry 1 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 20:57 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001069530-19-000049 · certent-form4.xml · derivative · entry 1 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Medical & Operating Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-12-13 F1 · derivative.exercise_date: Stock Options issued pursuant to the Company's Equity Incentive Plan vest over four (4) years at a rate of 1/48th each month. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 22:26 UTC | FILANA THERAPEUTICS, INC. PTIE · Entity 7294 | GrantStock Options(1) · Derivative | 50,000 | $0.95 Strike: $0.95 | $47,500.00 |
DisclosureSEC source: 0001069530-18-000046 · primary_doc.xml · derivative · entry 1 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Sientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,993 Underlying: Common Stock · 50,000 shares Expires 2028-09-14 Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 21:34 UTC | FILANA THERAPEUTICS, INC. PTIE · Entity 7294 | GrantStock Options(1) · Derivative | 250,000 | $3.24 Strike: $3.24 | $810,000.00 |
DisclosureSEC source: 0001069530-17-000034 · primary_doc.xml · derivative · entry 1 FRIEDMANN NADAV · CIK 0001245267 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639,238 Underlying: Common Stock · 250,000 shares Expires 2027-08-23 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.